Guidelines for vismodegib in the management of periocular basal cell carcinoma.

[1]  Roxana Del Aguila,et al.  Neoadjuvant Vismodegib and Mohs Micrographic Surgery for Locally Advanced Periocular Basal Cell Carcinoma. , 2019, Ophthalmic plastic and reconstructive surgery.

[2]  B. Esmaeli,et al.  Impact of Food and Drug Administration Approval of Vismodegib on Prevalence of Orbital Exenteration as a Necessary Surgical Treatment for Locally Advanced Periocular Basal Cell Carcinoma. , 2019, Ophthalmic plastic and reconstructive surgery.

[3]  B. Esmaeli,et al.  Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma , 2018, British Journal of Ophthalmology.

[4]  T. Olencki,et al.  Guidelines of care for the management of basal cell carcinoma. , 2018, Journal of the American Academy of Dermatology.

[5]  A. Hauschild,et al.  Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. , 2017, European journal of cancer.

[6]  A. Mittal,et al.  Skin Cancers in Organ Transplant Recipients , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  Xianqun Fan,et al.  Ocular basal cell carcinoma: a brief literature review of clinical diagnosis and treatment , 2017, OncoTargets and therapy.

[8]  A. Furdová,et al.  Periocular Basal Cell Carcinoma Predictors for Recurrence and Infiltration of the Orbit , 2016, The Journal of craniofacial surgery.

[9]  V. Elner,et al.  Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area , 2015, Ophthalmic plastic and reconstructive surgery.

[10]  Michelle T. Sun,et al.  Management of periorbital basal cell carcinoma with orbital invasion. , 2015, Future oncology.

[11]  Vivian T. Yin,et al.  Targeting EGFR and sonic hedgehog pathways for locally advanced eyelid and periocular carcinomas. , 2014, World journal of clinical cases.

[12]  H. Gill,et al.  Eyelid Margin Basal Cell Carcinoma Managed With Full-Thickness En-Face Frozen Section Histopathology , 2014, Ophthalmic plastic and reconstructive surgery.

[13]  A. Chang,et al.  Vismodegib for periocular and orbital basal cell carcinoma. , 2013, JAMA ophthalmology.

[14]  V. Elner,et al.  Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma. , 2013, JAMA ophthalmology.

[15]  Vivian T. Yin,et al.  Targeted Therapy for Orbital and Periocular Basal Cell Carcinoma and Squamous Cell Carcinoma , 2013, Ophthalmic plastic and reconstructive surgery.

[16]  Kris Chang,et al.  Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. , 2012, The New England journal of medicine.

[17]  Aleksandar Sekulic,et al.  Efficacy and safety of vismodegib in advanced basal-cell carcinoma. , 2012, The New England journal of medicine.

[18]  J. Leonardi-Bee,et al.  A systematic review of worldwide incidence of nonmelanoma skin cancer , 2012, The British journal of dermatology.

[19]  K. Tzannis,et al.  Epidemiologic risk factors of basal cell carcinoma development and age at onset in a Southern European population from Greece , 2011, Experimental dermatology.

[20]  K. Kusumoto,et al.  Clinical Outcome of Surgical Treatment for Periorbital Basal Cell Carcinoma , 2009, Annals of plastic surgery.

[21]  J. Dent,et al.  [The Montreal definition and classification of gastroesophageal reflux disease: a global, evidence-based consensus paper]. , 2007, Zeitschrift fur Gastroenterologie.

[22]  G. Kourt,et al.  Management of periocular basal and squamous cell carcinoma: a series of 485 cases. , 2006, American journal of ophthalmology.

[23]  J. Dent,et al.  The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus , 2006, The American Journal of Gastroenterology.

[24]  R. Ceilley,et al.  Current modalities and new advances in the treatment of basal cell carcinoma , 2006, International journal of dermatology.

[25]  S. Hamada,et al.  Eyelid basal cell carcinoma: non-Mohs excision, repair, and outcome , 2005, British Journal of Ophthalmology.

[26]  R. Malhotra,et al.  The Australian Mohs database, part II: periocular basal cell carcinoma outcome at 5-year follow-up. , 2004, Ophthalmology.

[27]  R. Goldberg,et al.  Orbital Exenteration: Results of an Individualized Approach , 2003, Ophthalmic plastic and reconstructive surgery.

[28]  K. Whitehead,et al.  Management of Periocular Basal Cell Carcinoma With Modified En Face Frozen Section Controlled Excision , 2002, Ophthalmic plastic and reconstructive surgery.

[29]  G. Bartley,et al.  Treatment options and future prospects for the management of eyelid malignancies: an evidence-based update. , 2001, Ophthalmology.

[30]  G. Bartley,et al.  Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted County, Minnesota. , 1999, Ophthalmology.

[31]  H. W. Randle.  Basal Cell Carcinoma Identification and Treatment of the High‐Risk Patient , 1996, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[32]  H. Glatt,et al.  Conventional frozen sections in periocular basal-cell carcinoma: a review of 236 cases. , 1992, Ophthalmic surgery.

[33]  F. Mohs.  Micrographic surgery for the microscopically controlled excision of eyelid cancers. , 1986, Archives of ophthalmology.